

Subject Index

A

- Adrenergic receptor blockade *8*: 110–111
- β -adrenergic receptor blocking drugs
 - adrenergic receptor blockade *8*: 110–111
 - alcohol withdrawal *8*: 117–118
 - anxiety states *8*: 112–117
 - morbid anxiety *8*: 112–116
 - physiological anxiety *8*: 117
 - drug dependence *8*: 118–120
 - hypertension *8*: 85
 - lithium-induced tremor *8*: 121
 - psychiatry *8*: 111–112
 - schizophrenia *8*: 120–121
 - side-effects *8*: 121–124
 - beta-blocking drugs *8*: 117–118
- Alfathesin *8*: 87–88
 - animal studies *8*: 99–102
 - anaesthetic properties *8*: 99–100
 - dysmorphology studies *8*: 102
 - effect on central nervous system *8*: 101
 - effect on veins *8*: 100–101
 - haemodynamic effects *8*: 100
 - hormonal effects *8*: 101
 - interaction with other anaesthetics *8*: 101–102
 - clinical pharmacology *8*: 93–99
 - anaesthetic effect *8*: 93–94
 - analgesic effect *8*: 98–99
 - cardiovascular effects *8*: 94–96
 - effect on muscle *8*: 94
 - effect on veins *8*: 97
 - respiratory effects *8*: 96–97
 - use with other anaesthetics *8*: 97
 - clinical studies *8*: 88–93
 - cardioversion *8*: 93
 - dental anaesthesia *8*: 92
 - induction of anaesthesia *8*: 89–90
 - intra-ocular surgery *8*: 92–93
 - obstetrics *8*: 93
 - psychiatry *8*: 92
 - sole anaesthetic agent *8*: 90
 - dosage *8*: 106
 - pharmacokinetic studies: animal *8*: 102–103
 - distribution *8*: 102–103
 - excretion *8*: 103
 - metabolism *8*: 103
 - plasma levels *8*: 102
 - protein binding *8*: 103
 - pharmacokinetic studies: human *8*: 99
 - precautions *8*: 105
 - side-effects *8*: 82, 104–105, 153
- Alphadolone acetate
 - combined with alphaxalone *8*: 87–108
- Alphaxalone
 - combined with alphadolone acetate *8*: 87–108
- Althesin
 - see alfathesin
- Anaemia, aplastic
 - drug-induced *8*: 147–148
- Anaesthesia
 - alfathesin *8*: 87–108
 - in hypertension *8*: 84–86
- Anaesthesia: dental
 - alfathesin *8*: 92
- Anaesthetics
 - side-effects *8*: 81–83
- Anaesthetics: intravenous
 - alfathesin *8*: 87–108
 - sensitivity *8*: 153–155
 - side-effects *8*: 82–83
- Antidepressants, tricyclic
 - use in elderly *8*: 134
- Anxiety
 - beta-blocking drugs *8*: 112–116

Subject Index

A

- Adrenergic receptor blockade *8*: 110–111
- β -adrenergic receptor blocking drugs
 - adrenergic receptor blockade *8*: 110–111
 - alcohol withdrawal *8*: 117–118
 - anxiety states *8*: 112–117
 - morbid anxiety *8*: 112–116
 - physiological anxiety *8*: 117
 - drug dependence *8*: 118–120
 - hypertension *8*: 85
 - lithium-induced tremor *8*: 121
 - psychiatry *8*: 111–112
 - schizophrenia *8*: 120–121
 - side-effects *8*: 121–124
 - beta-blocking drugs *8*: 117–118
- Alfathesin *8*: 87–88
 - animal studies *8*: 99–102
 - anaesthetic properties *8*: 99–100
 - dysmorphology studies *8*: 102
 - effect on central nervous system *8*: 101
 - effect on veins *8*: 100–101
 - haemodynamic effects *8*: 100
 - hormonal effects *8*: 101
 - interaction with other anaesthetics *8*: 101–102
 - clinical pharmacology *8*: 93–99
 - anaesthetic effect *8*: 93–94
 - analgesic effect *8*: 98–99
 - cardiovascular effects *8*: 94–96
 - effect on muscle *8*: 94
 - effect on veins *8*: 97
 - respiratory effects *8*: 96–97
 - use with other anaesthetics *8*: 97
 - clinical studies *8*: 88–93
 - cardioversion *8*: 93
 - dental anaesthesia *8*: 92
 - induction of anaesthesia *8*: 89–90
 - intra-ocular surgery *8*: 92–93
 - obstetrics *8*: 93
 - psychiatry *8*: 92
 - sole anaesthetic agent *8*: 90
 - dosage *8*: 106
 - pharmacokinetic studies: animal *8*: 102–103
 - distribution *8*: 102–103
 - excretion *8*: 103
 - metabolism *8*: 103
 - plasma levels *8*: 102
 - protein binding *8*: 103
 - pharmacokinetic studies: human *8*: 99
 - precautions *8*: 105
 - side-effects *8*: 82, 104–105, 153
- Alphadolone acetate
 - combined with alphaxalone *8*: 87–108
- Alphaxalone
 - combined with alphadolone acetate *8*: 87–108
- Althesin
 - see alfathesin
- Anaemia, aplastic
 - drug-induced *8*: 147–148
- Anaesthesia
 - alfathesin *8*: 87–108
 - in hypertension *8*: 84–86
- Anaesthesia: dental
 - alfathesin *8*: 92
- Anaesthetics
 - side-effects *8*: 81–83
- Anaesthetics: intravenous
 - alfathesin *8*: 87–108
 - sensitivity *8*: 153–155
 - side-effects *8*: 82–83
- Antidepressants, tricyclic
 - use in elderly *8*: 134
- Anxiety
 - beta-blocking drugs *8*: 112–116

treatment in elderly *8*: 136

Aplastic anaemia
see anaemia, aplastic
Azathioprine
hepatitis *8*: 141

B

Biliary tract disease
corticosteroids *8*: 145
Butyrophenones
use in elderly *8*: 135–136

C

Cardioversion
alfathesin *8*: 93
Chloroquine
porphyria cutanea tarda *8*: 152
Cholangiohepatitis
corticosteroids *8*: 145
Cirrhosis
corticosteroids *8*: 144
Corticosteroids
clinical use
biliary tract disease *8*: 145
cholangiohepatitis *8*: 145
cholestrasis *8*: 139–140
chronic hepatitis *8*: 140
cirrhosis *8*: 144
drug-induced liver disease *8*: 144
extrahepatic obstruction *8*: 145
fulminant hepatitis *8*: 140
hepatitis, active chronic *8*: 140–143
liver disease *8*: 139–145
viral hepatitis *8*: 139

D

Dental anaesthesia see anaesthesia: dental
Depression
treatment in elderly *8*: 134
Drug dependence
beta-blocking drugs *8*: 118–120
Drug-induced disease
aplastic anaemia *8*: 147–148
Drug reactions, adverse
alfathesin *8*: 104–105, 153
anaesthetics *8*: 81–83, 153–157
beta-blocking drugs *8*: 121–124
halothane *8*: 81–82, 155–157
pentazocine *8*: 149–150
rifampicin *8*: 148–149

E

Eclampsia *8*: 129–130
Elderly
psychotherapeutic drugs *8*: 132–138

G

Geriatric pharmacology
psychotherapeutic drugs *8*: 132–138

H

Haemolysis
due to rifampicin *8*: 148–149
Halofenate
uricosuric action *8*: 146
Halothane
jaundice *8*: 81–82, 155–157
Heparin
prevention of thrombosis *8*: 152–153
Hepatitis
Corticosteroids *8*: 140–143
Hepatotoxicity
halothane *8*: 81–82, 155–157
Hydrocortisone
fulminant hepatitis *8*: 140
Hypertension
anaesthesia *8*: 84–86
in pregnancy *8*: 125–131
detection *8*: 125–126
eclampsia *8*: 129–130
labour *8*: 130–131
management *8*: 126–129
when to hospitalise *8*: 126
Hypnotic drugs
use in elderly *8*: 136–137

I

Immunosuppressive drugs
liver disease *8*: 139–145
Insomnia
treatment in elderly *8*: 136–137

K

Ketamine
compared with alfathesin *8*: 95–96

L

Lithium
side-effects
beta-blocking drugs *8*: 121
use in elderly *8*: 134–135
Liver disease
treatment with corticosteroids *8*: 139–145

M

Mania
treatment in elderly *8*: 134–135
Methohexitone

- compared with alfathesin 8: 90, 92, 95, 97
- Methotrexate
 - effect on liver 8: 151
 - psoriasis 8: 151

O

- Obstetrics
 - alfathesin 8: 93

P

- D-Penicillamine
 - scleroderma 8: 157
- Pentazocine
 - central nervous system effects 8: 149-150
 - colonic response 8: 150-151
 - side-effects 8: 149-150
- Phenothiazines
 - use in elderly 8: 135-136
- Porphyria cutanea tarda
 - chloroquine 8: 152
- Practolol
 - psychiatry 8: 109-124
- Prednisolone
 - hepatitis 8: 140-141
- Pregnancy
 - hypertension 8: 125-131
- Propanidid
 - compared with alfathesin 8: 90, 97
 - side-effects 8: 82, 154
- Propranolol
 - psychiatry 8: 109-124
- Proteinuria
 - in pregnancy 8: 127
- Psoriasis
 - methotrexate 8: 151
- Psychiatric disorders
 - in the elderly 8: 133
- Psychiatry
 - alfathesin 8: 92

- Psychotherapeutic drugs
 - use in the elderly 8: 132-138
 - anxiety states 8: 136
 - depression 8: 134
 - general principles 8: 132-133
 - insomnia 8: 136-137
 - mania 8: 134-135
 - organic psychoses 8: 136
 - schizophrenia 8: 135-136

R

- Rifampicin
 - side-effects 8: 148-149

S

- Schizophrenia
 - beta-blocking drugs 8: 120-121
 - treatment in elderly 8: 135-136
- Scleroderma
 - D-penicillamine 8: 157
- Skin cancer
 - see cancer, skin
- Sotalol
 - psychiatry 8: 109-124

T

- Thiopentone
 - compared with alfathesin 8: 88-90, 93, 95, 97
 - side-effects 8: 82-83
- Thrombosis
 - prevention after myocardial infarction 8: 152-153
- Tremor
 - beta-blocking drugs 8: 121

U

- Uricosuric action
 - halofenate 8: 146

Modern Problems of Pharmacopsychiatry

Series Editors: *Th.A. Ban* (Montreal, Que.), *F.A. Freyhan* (Washington, D.C.),
P. Pichot (Paris) and *W. Pöldinger* (Vienna)

Vol. 9 Trazodone

Proceedings of the First International Symposium, Montreal 1973

Volume Editors: *Th.A. Ban* (Montreal, Que.) and
B. Silvestrini (Rome)

VI + 210 p., 86 fig., 83 tab., 1974

SFr. 75.- / US \$ 27.50 / DM 71.- / £ 10.90

ISBN 3-8055-1718-1

List of Contributors:

B. Silvestrini, V.G. Longo and A. Scotti de Carolis (Rome), *K. Yamatsu, T. Kaneko, Y. Yamanishi, A. Kitahara and S. Ohtake* (Tokyo), *J.R. Boissier, E. Portmann-Cristesco, P. Soubrié and J. Fichelle* (Paris), *S. Garattini* (Milan), *G.L. Gatti* (Rome), *E.F. Domino* (Ann Arbor, Mich.), *T. Fujita, C. Yamato and T. Takahashi* (Tokyo), *L. Angelucci and P. Bolle* (Rome), *K.F. Rivett* (Huntingdon), *P. Scorza Barcellona* (Rome), *Y. Suzuki* (Tokyo), *Th.A. Ban, M.M. Amin, N.P.V. Nair and F. Engelsman* (Montreal, Que.), *F. Antonelli, M. De Gregorio, A. Dionisio and D. Peruzi* (Rome), *S. Miura* (Sagamihara), *D. Schwarz and M. Blendl* (Munich), *A. Lopez Zanon* (Madrid), *R. Montanini* (Varese), *G. Gunella* (Bologna), *Y. Shibahara* (Kyoto), *F. Pariente, A. Muratorio, C. Maggini, G. Coccagna and M. Guazzelli* (Pisa), *A. Agnoli, M. Piccione, M. Casacchia and C. Fazio* (Rome), *G.B. Cassano, P. Castrogiovanni and L. Conti* (Pisa), *J. Saarma* (Tartu, USSR)

Recent advances in psychopharmacotherapy seem to follow established avenues of specific substances belonging to well-known groups. New avenues can only be opened and explored through original molecules totally unrelated to known chemical families of psychoactive usefulness. Trazodone appears to be such a novelty and the International Symposium held in Montreal on October 5 and 6, 1973 confirms the importance of this new substance both from a point of view of applied therapeutic sciences as well as scientific research. The publication of the proceedings of this Symposium may represent a major contribution to the knowledge of modern psychopharmacotherapy.



S. Karger · Basel · München · Paris · London · New York · Sydney

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaforth, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopoeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright © 1974 Australasian Drug Information Services Pty Limited. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form	
Please enter my subscription for <i>Drugs</i> beginning with	
<input type="checkbox"/> Vol. 1, 1971	<input type="checkbox"/> Vol. 4, 1972 <input type="checkbox"/> Vol. 7, 1974
<input type="checkbox"/> Vol. 2, 1971	<input type="checkbox"/> Vol. 5, 1973 <input type="checkbox"/> Vol. 8, 1974
<input type="checkbox"/> Vol. 3, 1972	<input type="checkbox"/> Vol. 6, 1973
Name _____	
Title _____	
Address _____	
City _____	
State/Zip _____	
Bundesrepublik Deutschland: S. Karger GmbH, Postfach 2, D-8034 Germering/München France: S. Karger S.A., 42bis, Bd de La Tour-Maubourg, F-75 Paris 7e Great Britain: John Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex USA: Albert J. Phiebig Inc., US Representative of S. Karger, P.O. Box 352, White Plains, NY 10602 Australia: Australasian Drug Information Services Pty. Ltd., Agents in Australasia for S. Karger, P.O. Box 194, Balgowlah/Sydney, NSW 2093 New Zealand: Australasian Drug Information Services Pty. Ltd., New Zealand Office, P.O. Box 34-030, Birkenhead, Auckland 10	

